中草药

中药调控OPG/RANK/RANKL信号通路干预乳腺癌骨转移的机制研究进展

PDF下载

中草药 | 综述 2026,57(4): 1492-1505

收起

中草药 |综述 2026 , 57 (4) : 1492 -1505

中药调控OPG/RANK/RANKL信号通路干预乳腺癌骨转移的机制研究进展

全屏

王依雯¹, 高晴琪¹, 周康钰¹, 张庆林², 张扬¹, 吴美兰³, 寿旦¹

作者信息

通讯作者:

寿旦

作者简介:

王依雯: 王依雯，女，硕士研究生，研究方向为药物分析学。E-mail:evenwang0309@126.com

Research progress on mechanisms of traditional Chinese medicine in regulating OPG/RANK/RANKL signaling pathway for intervention of breast cancer bone metastasis

WANG Yiwen, GAO Qingqi, ZHOU Kangyu, ZHANG Qinglin, ZHANG Yang, WU Meilan, SHOU Dan

Affiliations

doi: 10.7501/j.issn.0253-2670.2026.04.025

文章导航

摘要

收起

乳腺癌骨转移（breast cancer bone metastasis，BCBM）是乳腺癌常见并发症，容易引起骨痛、病理性骨折和高钙血症等。骨保护素（osteoprotegerin，OPG）/核因子-κB受体活化因子（receptor activator of nuclear factor-κB，RANK）/RANK配体（RANK ligand，RANKL）信号通路在BCBM的发生发展中具有重要作用。研究表明，该信号通路与破骨细胞活化密切相关；BCBM的临床治疗策略包括骨改良药物、分子靶向治疗、免疫疗法等；中药单体及复方制剂能够上调OPG表达抑制破骨细胞活化，并阻断RANKL介导的核因子-κB信号通路激活，从而抑制BCBM病理进程。然而中药的临床应用仍受限于药动学特征的不确定性、质量标准不完善及疗效差异等因素。通过阐述BCBM中OPG/RANK/RANKL信号通路的调控机制，为中药治疗策略的制定提供理论依据。

关键词

乳腺癌骨转移 / 骨保护素/核因子-κB受体活化因子/核因子-κB受体活化因子配体 / 骨破坏 / 治疗策略 / 中药

Abstract

收起

Breast cancer bone metastasis (BCBM) is a common complication of breast cancer, which often induces bone pain, pathologic fractures, hypercalcemia, etc. The osteoprotegerin (OPG)/receptor activator of nuclear factor-κB (RANK)/RANK ligand (RANKL) signaling pathway plays a crucial role in development and progression of BCBM. Results has shown that this signaling pathway is closely related to osteoclast activation. The clinical treatment strategies for BCBM include bone-modifying drugs, molecularly targeted therapies, and immunotherapies. Both traditional Chinese medicine (TCM) monomers and compound preparations are able to upregulate OPG expression to inhibit osteoclast activation and block the RANKL-mediated nuclear factor-κB signaling pathway activation, thereby suppressing the pathological progression of BCBM. However, the clinical application of TCM is still limited by factors such as uncertain pharmacokinetic characteristics, incomplete quality standards, and variations in therapeutic efficacy. Elucidating the regulatory mechanisms of the OPG/RANK/RANKL signaling pathway in BCBM may therefore provide a theoretical foundation for developing TCM-based treatment strategies.

Key words

breast cancer bone metastasis / OPG/RANK/RANKL / bone destruction / treatment strategies / traditional Chinese medicine

引用本文

王依雯, 高晴琪, 周康钰, 张庆林, 张扬, 吴美兰, 寿旦. 中药调控OPG/RANK/RANKL信号通路干预乳腺癌骨转移的机制研究进展. 中草药, 2026 , 57 (4) : 1492 -1505 . DOI: 10.7501/j.issn.0253-2670.2026.04.025

WANG Yiwen, GAO Qingqi, ZHOU Kangyu, ZHANG Qinglin, ZHANG Yang, WU Meilan, SHOU Dan. Research progress on mechanisms of traditional Chinese medicine in regulating OPG/RANK/RANKL signaling pathway for intervention of breast cancer bone metastasis[J]. Chinese Traditional and Herbal Drugs, 2026 , 57 (4) : 1492 -1505 . DOI: 10.7501/j.issn.0253-2670.2026.04.025

基金

收起

国家自然科学基金资助项目 (82474144); 浙江省万人计划科技创新领军人才项目 (2022R52031); 浙江中医药大学科研资助项目 (2025JKZDZC04)

参考文献

收起

文献

收起

参考文献引证文献

排序方式：

鲍敏, 陈群, 赵森. 中药治疗乳腺癌的药理作用机制和临床应用研究进展[J]. 中草药, 2025, 56(21): 7983-7994.
Zuo H, Yang D B, Yang Q W, et al. Differential regulation of breast cancer bone metastasis by PARP1 and PARP2[J]. Nat Commun, 2020, 11(1): 1578.
郭卫. 乳腺癌骨转移临床诊疗专家共识[J]. 中国肿瘤临床, 2022, 49(13): 660-669.
王亮, 卫宜锐, 黄博臻, 等. 中医药治疗乳腺癌骨转移研究进展[J]. 光明中医, 2025, 40(4): 786-790.
Yao Y B, Zheng X E, Luo X B, et al. Incidence, prognosis and nomograms of breast cancer with bone metastases at initial diagnosis: A large population-based study [J]. Am J Transl Res, 2021, 13(9): 10248-10261.
杨争, 胡金辉, 王希, 等. 补肾活血汤对SDF-1α诱导的人乳腺癌MDA-MB-231细胞增殖及迁移的影响[J]. 时珍国医国药, 2016, 27(8): 1868-1870.
Sun X, Li K X, Hase M, et al. Suppression of breast cancer-associated bone loss with osteoblast proteomes via HSP90ab1/moesin-mediated inhibition of TGFβ/FN1/ CD44 signaling [J]. Theranostics, 2022, 12(2): 929-943.
卜寒梅, 王世坤, 李远栋, 等. 补肾中药基于OPG/ RANKL/RANK信号通路对原发性骨质疏松症作用机制的研究进展[J]. 中草药, 2022, 53(10):3209-3217.
Li Z, Ouyang Y J, Yuan X Y, et al. Essential role of RANK-NF-κB signaling pathway in spinal deformities: Insights from largemouth bass and zebrafish models [J]. Aquaculture, 2025, 606: 742570.
Li Y X, Liu F S, Cai Q J, et al. Invasion and metastasis in cancer: Molecular insights and therapeutic targets [J]. Signal Transduct Target Ther, 2025, 10(1): 57.
Wei R J, Zeng Z Y, Chen S, et al. Qingfei Litan Decoction alleviated Klebsiella pneumoniae-induced pneumonia by targeting the TLR4/MyD88/NF-κB axis via miR-146a-5p [J]. J Ethnopharmacol, 2025, 349: 119947.
Anzai M, Watanabe-Takahashi M, Kawabata H, et al. Clustered peptide regulating the multivalent interaction between RANK and TRAF6 inhibits osteoclastogenesis by fine-tuning signals [J]. Commun Biol, 2025, 8(1): 643.
Renema N, Navet B, Heymann M F, et al. RANK-RANKL signalling in cancer [J]. Biosci Rep, 2016, 36(4): e00366.
De Leon-Oliva D, Barrena-Blázquez S, Jiménez-Álvarez L, et al. The RANK-RANKL-OPG system: A multifaceted regulator of homeostasis, immunity, and cancer [J]. Medicina, 2023, 59(10): 1752.
Sisay M, Mengistu G, Edessa D. The RANK/RANKL/ OPG system in tumorigenesis and metastasis of cancer stem cell: Potential targets for anticancer therapy [J]. Onco Targets Ther, 2017, 10: 3801-3810.
张玉琴, 孙承韬, 王宏运, 等. 天料木中异香豆素糖苷化合物对MC3T3-E1细胞增殖、分化及OPG/RANKL/ RANK信号通路的影响[J]. 药物评价研究, 2019, 42(8): 1515-1519.
Liang H Y, Yin G L, Feng D D, et al. Ras-proximate-1(RAP1): A prognosis and therapeutic target in the metastatic spread of breast cancer [J]. Clin Exp Metastasis, 2025, 42(3): 23.
de Visser K E, Joyce J A. The evolving tumor microenvironment: From cancer initiation to metastatic outgrowth [J]. Cancer Cell, 2023, 41(3): 374-403.
张文博, 杨勇. 乳腺癌骨转移研究进展[J]. 药学进展, 2024, 48(8): 625-632.
Guise T A, Mohammad K S, Clines G, et al. Basic mechanisms responsible for osteolytic and osteoblastic bone metastases [J]. Clin Cancer Res, 2006, 12(20 Pt2): 6213s-6216s.
Swami S, Zhu H, Nisco A, et al. Parathyroid hormone 1 receptor signaling mediates breast cancer metastasis to bone in mice [J]. JCI Insight, 2023, 8(5): e157390.
Xu J T, Gao F Y, Liu W C, et al. Cell-cell communication characteristics in breast cancer metastasis [J]. Cell Commun Signal, 2024, 22(1): 55.
Northey J J, Hayward M K, Yui Y, et al. Mechanosensitive hormone signaling promotes mammary progenitor expansion and breast cancer risk [J]. Cell Stem Cell, 2024, 31(1): 106-126.
Rao S, Cronin S J F, Sigl V, et al. RANKL and RANK: From mammalian physiology to cancer treatment [J]. Trends Cell Biol, 2018, 28(3): 213-223.
Mathis K M, Sturgeon K M, Winkels R M, et al. Bone resorption and bone metastasis risk [J]. Med Hypotheses, 2018, 118: 36-41.
Kitaura H, Marahleh A, Ohori F, et al. Osteocyte-related cytokines regulate osteoclast formation and bone resorption [J]. Int J Mol Sci, 2020, 21(14): 5169.
Wu Z Q, Wang T, Fang M, et al. MFAP5 promotes tumor progression and bone metastasis by regulating ERK/MMP signaling pathways in breast cancer [J]. Biochem Biophys Res Commun, 2018, 498(3): 495-501.
Deng M M, Ding H, Zhou Y R, et al. Cancer metastasis to the bone: Mechanisms and animal models (Review) [J]. Oncol Lett, 2025, 29(5): 221.
Gong H, Li Y X, Yang W, et al. PRODH2-mediated metabolism in the bone microenvironment promotes breast cancer metastasis [J]. Cancer Res, 2025, 85(21): 4198-4211.
Wang Y W, Luo C W. Unveiling the signal valve specifically tuning the TGF-β1 suppression of osteogenesis: Mediation through a Smad1-Smad2 complex [J]. Cell Commun Signal, 2025, 23(1): 38.
Landini L, Marini M, Souza Monteiro de Araujo D, et al. Schwann cell insulin-like growth factor receptor type-1 mediates metastatic bone cancer pain in mice [J]. Brain Behav Immun, 2023, 110: 348-364.
Le Pape F, Vargas G, Clézardin P. The role of osteoclasts in breast cancer bone metastasis [J]. J Bone Oncol, 2016, 5(3): 93-95.
Das S, Clézardin P, Kamel S, et al. The CaSR in pathogenesis of breast cancer: A new target for early stage bone metastases [J]. Front Oncol, 2020, 10: 69.
Chan Y T, Lin R J, Wang Y H, et al. The interplay between IGF-1R signaling and Hippo-YAP in breast cancer stem cells [J]. Cell Commun Signal, 2023, 21(1): 81.
Lin A Y, Kitaura H, Ohori F, et al. (D-Ala²) GIP inhibits inflammatory bone resorption by suppressing TNF-α and RANKL expression and directly impeding osteoclast formation [J]. Int J Mol Sci, 2024, 25(5): 2555.
Ming J, Cronin S J F, Penninger J M. Targeting the RANKL/RANK/OPG axis for cancer therapy [J]. Front Oncol, 2020, 10: 1283.
Gómez-Aleza C, González-Suárez E. Inhibition of RANK signaling as a potential immunotherapy in breast cancer [J]. Oncoimmunology, 2021, 10(1): 1923156.
Elango J, Bao B, Wu W H. The hidden secrets of soluble RANKL in bone biology [J]. Cytokine, 2021, 144: 155559.
Lungu O, Toscani D, Giuliani N. Mechanistic insights into bone destruction in multiple myeloma: Cellular and molecular perspectives [J]. J Bone Oncol, 2025, 51: 100668.
Guan Z Y, Yuan W Q, Jia J L, et al. Bone mass loss in chronic heart failure is associated with sympathetic nerve activation [J]. Bone, 2023, 166: 116596.
Kim J M, Lin C J, Stavre Z, et al. Osteoblast-osteoclast communication and bone homeostasis [J]. Cells, 2020, 9(9): 2073.
Straburzyńska-Lupa A, Cisoń T, Gomarasca M, et al. Sclerostin and bone remodeling biomarkers responses to whole-body cryotherapy (�℃) in healthy young men with different physical fitness levels [J]. Sci Rep, 2021, 11(1): 16156.
Kim O, Tran P T, Gal M, et al. RAS-stimulated release of exosomal miR-494-3p promotes the osteolytic bone metastasis of breast cancer cells [J]. Int J Mol Med, 2023, 52(3): 84.
Hu H T, Li X, Xu Z N, et al. OPG promotes lung metastasis by reducing CXCL10 production of monocyte-derived macrophages and decreasing NK cell recruitment [J]. EBioMedicine, 2025, 111: 105503.
Ma G X, Cheng S Y, Han Y Y, et al. The p53-miR17 family-RANKL axis bridges liver-bone communication [J]. Mol Ther, 2025, 33(2): 631-648.
Bishop R T, Marino S, Carrasco G, et al. Combined administration of a small-molecule inhibitor of TRAF6 and Docetaxel reduces breast cancer skeletal metastasis and osteolysis [J]. Cancer Lett, 2020, 488: 27-39.
Wu X Q, Li F F, Dang L, et al. RANKL/RANK system-based mechanism for breast cancer bone metastasis and related therapeutic strategies [J]. Front Cell Dev Biol, 2020, 8: 76.
Takeda T, Tsubaki M, Genno S, et al. RANK/RANKL axis promotes migration, invasion, and metastasis of osteosarcoma via activating NF-κB pathway [J]. Exp Cell Res, 2024, 436(2): 113978.
Maeda K, Kobayashi Y, Udagawa N, et al. Wnt5a-Ror2 signaling between osteoblast-lineage cells and osteoclast precursors enhances osteoclastogenesis [J]. Nat Med, 2012, 18(3): 405-412.
Chen K, Ng P Y, Chen R Y, et al. Sfrp4 repression of the Ror2/Jnk cascade in osteoclasts protects cortical bone from excessive endosteal resorption [J]. Proc Natl Acad Sci USA, 2019, 116(28): 14138-14143.
Han Y X, Katayama S, Futakuchi M, et al. Targeting c-Jun is a potential therapy for luminal breast cancer bone metastasis [J]. Mol Cancer Res, 2023, 21(9): 908-921.
Li X X, Liang Y J, Lian C, et al. CST6 protein and peptides inhibit breast cancer bone metastasis by suppressing CTSB activity and osteoclastogenesis [J]. Theranostics, 2021, 11(20): 9821-9832.
Drago J Z, Formisano L, Juric D, et al. FGFR1 amplification mediates endocrine resistance but retains TORC sensitivity in metastatic hormone receptor-positive (HR⁺) breast cancer [J]. Clin Cancer Res, 2019, 25(21): 6443-6451.
Zhong Z Y, Zhang C J, Ni S, et al. NFATc1-mediated expression of SLC7A11 drives sensitivity to TXNRD1 inhibitors in osteoclast precursors [J]. Redox Biol, 2023, 63: 102711.
Liu X Y, Ma R, Wei F, et al. Tumor-derived exosomal lncRNA-MIR193BHG promotes bone metastasis of breast cancer by targeting the miR-489-3p/DNMT3A signaling axis in osteoclasts [J]. J Transl Med, 2025, 23(1): 142.
Tada H, Miyashita M, Harada-Shoji N, et al. Clinicopathogenomic analysis of PI3K/Akt/PTEN-altered luminal metastatic breast cancer in Japan [J]. Breast Cancer, 2025, 32(1): 208-216.
Lin Q, Fang X L, Liang G H, et al. Silencing CTNND1 mediates triple-negative breast cancer bone metastasis via upregulating CXCR4/CXCL12 axis and neutrophils infiltration in bone [J]. Cancers, 2021, 13(22): 5703.
Behzatoglu K. Osteoclasts in tumor biology: Metastasis and epithelial-mesenchymal-myeloid transition [J]. Pathol Oncol Res, 2021, 27: 609472.
Inoue Y, Abe K, Onozaki K, et al. TGF-β decreases the stability of IL-18-induced IFN-γ mRNA through the expression of TGF-β-induced tristetraprolin in KG-1 cells [J]. Biol Pharm Bull, 2015, 38(4): 536-544.
Beal A M, Ramos-Hernández N, Riling C R, et al. TGF-β induces the expression of the adaptor Ndfip1 to silence IL-4 production during iTreg cell differentiation [J]. Nat Immunol, 2011, 13(1): 77-85.
Tunyogi-Csapo M, Kis-Toth K, Radacs M, et al. Cytokine-controlled RANKL and osteoprotegerin expression by human and mouse synovial fibroblasts: Fibroblast-mediated pathologic bone resorption [J]. Arthritis Rheum, 2008, 58(8): 2397-2408.
Simatou A, Sarantis P, Koustas E, et al. The role of the RANKL/RANK axis in the prevention and treatment of breast cancer with immune checkpoint inhibitors and anti-RANKL [J]. Int J Mol Sci, 2020, 21(20): 7570.
Lin J Q, Ye S H, Ke H, et al. Changes in the mammary gland during aging and its links with breast diseases [J]. Acta Biochim Biophys Sin, 2023, 55(6): 1001-1019.
Levescot A, Chang M H, Schnell J, et al. IL-1β-driven osteoclastogenic Tregs accelerate bone erosion in arthritis [J]. J Clin Invest, 2021, 131(18): e141008.
陈蕊, 成洪聚. 破骨细胞在肿瘤骨转移多学科治疗中的研究进展[J]. 中国肿瘤临床, 2025, 52(4): 202-206.
Jules J, Zhang P, Ashley J W, et al. Molecular basis of requirement of receptor activator of nuclear factor κB signaling for interleukin 1-mediated osteoclastogenesis [J]. J Biol Chem, 2012, 287(19): 15728-15738.
肖青松, 覃拉拉, 丰哲. 乳腺癌骨转移新型疗法及靶点的研究进展[J]. 中国骨与关节杂志, 2025, 14(5): 476-480.
Adams A, Jakob T, Huth A, et al. Bone-modifying agents for reducing bone loss in women with early and locally advanced breast cancer: A network Meta-analysis [J]. Cochrane Database Syst Rev, 2024, 7(7): CD013451.
Blair H A. Inavolisib: First approval [J]. Drugs, 2025, 85(2): 271-278.
Nasrollahi E, Davar D. Immunomodulatory effects of RANK/RANKL blockade in patients with cancer [J]. Cancer Immunol Res, 2024, 12(4): 383-384.
Scafetta R, Donato M, Gullotta C, et al. Comparative analysis of denosumab and zoledronic acid in advanced breast cancer patients receiving CDK4/6 inhibitors [J]. Breast, 2025, 82: 104502.
Coleman R, Zhou Y, Jandial D, et al. Bone health outcomes from the international, multicenter, randomized, phase 3, placebo-controlled D-CARE study assessing adjuvant denosumab in early breast cancer [J]. Adv Ther, 2021, 38(8): 4569-4580.
Diel I J, Body J J, Stopeck A T, et al. The role of denosumab in the prevention of hypercalcaemia of malignancy in cancer patients with metastatic bone disease [J]. Eur J Cancer, 2015, 51(11): 1467-1475.
Jiang L H, Cui X H, Ma H N, et al. Comparison of denosumab and zoledronic acid for the treatment of solid tumors and multiple myeloma with bone metastasis: A systematic review and meta-analysis based on randomized controlled trials [J]. J Orthop Surg Res, 2021, 16(1): 400.
Sagdeo A, Elshehawy M, Rakieh C, et al. Severe hypocalcemia and hypophosphatemia following Denosumab administration in a multi-comorbidity patient [J]. Med Pharm Rep, 2025, 98(1): 144-148.
Sano M, Iijima Y, Yamada M, et al. Prevalence of bisphosphonate and denosumab use in elderly care facilities: Implications for the management of medication-related osteonecrosis of the jaw [J]. Cureus, 2025, 17(5): e83490.
Huang S Y, Yoon S S, Shimizu K, et al. Denosumab versus zoledronic acid in bone disease treatment of newly diagnosed multiple myeloma: An international, double-blind, randomized controlled phase 3 study-Asian subgroup analysis [J]. Adv Ther, 2020, 37(7): 3404-3416.
Dhillon S. Zoledronic acid (Reclast^®, Aclasta^®): A review in osteoporosis [J]. Drugs, 2016, 76(17): 1683-1697.
Coleman R. Bone-targeted agents and metastasis prevention [J]. Cancers, 2022, 14(15): 3640.
Wang Z J, Su X, Shi D L, et al. Evaluate the renal system damage caused by zoledronic acid: A comprehensive analysis of adverse events from FAERS [J]. BMC Cancer, 2024, 24(1): 1520.
Zhu K R, Wu Y Q, He P, et al. PI3K/Akt/mTOR-targeted therapy for breast cancer [J]. Cells, 2022, 11(16): 2508.
Zhang G C, Wang Y L, Chen B, et al. Characterization of frequently mutated cancer genes in Chinese breast tumors: A comparison of Chinese and TCGA cohorts [J]. Ann Transl Med, 2019, 7(8): 179.
Turner N C, Im S A, Saura C, et al. INAVO120: Phase III trial final overall survival (OS) analysis of first-line inavolisib (INAVO)/placebo (PBO) + palbociclib (PALBO) + fulvestrant (FULV) in patients (pts) with PIK3CA-mutated, hormone receptor-positive (HR+), HER2-negative (HER2–), endocrine-resistant advanced breast cancer (aBC) [J]. J Clin Oncol, 2025, 43(16_suppl): 1003.
Takayanagi H, Ogasawara K, Hida S, et al. T-cell-mediated regulation of osteoclastogenesis by signalling cross-talk between RANKL and IFN-gamma [J]. Nature, 2000, 408(6812): 600-605.
Cheng J N, Jin Z, Su C X, et al. Bone metastases diminish extraosseous response to checkpoint blockade immunotherapy through osteopontin-producing osteoclasts [J]. Cancer Cell, 2025, 43(6): 1093-1107.
Arellano D L, Juárez P, Verdugo-Meza A, et al. Bone microenvironment-suppressed T cells increase osteoclast formation and osteolytic bone metastases in mice [J]. J Bone Miner Res, 2022, 37(8): 1446-1463.
Wang Y X, Xu Z, Wu K L, et al. Siglec-15/sialic acid axis as a central glyco-immune checkpoint in breast cancer bone metastasis [J]. Proc Natl Acad Sci USA, 2024, 121(5): e2312929121.
Massy E, Confavreux C B, Point M, et al. Contribution of the immune bone marrow microenvironment to tumor growth and bone deconstruction: Implications for improving immunotherapeutic strategies in bone metastasis [J]. Neoplasia, 2025, 69: 101224.
Zhang D H, Long M L, Meng L C, et al. Molecular mechanisms of bone metastasis in breast cancer based on transcriptomic and microbiomic analysis [J]. Cancer Causes Control, 2025, 36(12): 1851-1868.
Zhang C, Qi L S, Cai J, et al. Clinicomics-guided distant metastasis prediction in breast cancer via artificial intelligence [J]. BMC Cancer, 2023, 23(1): 239.
Saeed S, Paez D, Estrada Lobato E, et al. [¹⁷⁷Lu] Lu-EDTMP-a bone pain palliating agent: Pharmacokinetics, biodistribution, safety profile and clinical evaluation in osseous metastatic patients [J]. Eur J Nucl Med Mol Imaging, 2025, 52(10): 3757-3772.
Tian Z R, Wu L, Yu C F, et al. Harnessing the power of antibodies to fight bone metastasis [J]. Sci Adv, 2021, 7(26): eabf2051.
Huang W, Wu X Y, Zhao Y F, et al. Janus-inspired core-shell structure hydrogel programmatically releases melatonin for reconstruction of postoperative bone tumor [J]. ACS Appl Mater Interfaces, 2023, 15(2): 2639-2655.
罗兴训, 张燕, 朱军, 等. 中药治疗乳腺癌骨转移的机制研究进展[J]. 山西医药杂志, 2015, 44(23): 2752-2755.
He S, Wang S S, Liu S Q, et al. Baicalein potentiated M1 macrophage polarization in cancer through targeting PI3Kγ/NF-κB signaling [J]. Front Pharmacol, 2021, 12: 743837.
Lee S K, Park K K, Kim K R, et al. Isoliquiritigenin inhibits metastatic breast cancer cell-induced receptor activator of nuclear factor kappa-B ligand/osteoprotegerin ratio in human osteoblastic cells [J]. J Cancer Prev, 2015, 20(4): 281-286.
Sun X Y, Zhang J, Wang Z J, et al. Licorice isoliquiritigenin-encapsulated mesoporous silica nanoparticles for osteoclast inhibition and bone loss prevention [J]. Theranostics, 2019, 9(18): 5183-5199.
Kim B, Lee K Y, Park B. Icariin abrogates osteoclast formation through the regulation of the RANKL-mediated TRAF6/NF-κB/ERK signaling pathway in RAW264.7 cells [J]. Phytomedicine, 2018, 51: 181-190.
Gao S H, Zhang X Y, Liu J, et al. Icariin induces triple-negative breast cancer cell apoptosis and suppresses invasion by inhibiting the JNK/c-Jun signaling pathway [J]. Drug Des Devel Ther, 2023, 17: 821-836.
Hong O Y, Jang H Y, Park K H, et al. Triptolide inhibits matrix metalloproteinase-9 expression and invasion of breast cancer cells through the inhibition of NF-κB and AP-1 signaling pathways [J]. Oncol Lett, 2021, 22(1): 562.
Li Y, Zhou X Y, Liu J L, et al. Dihydroartemisinin inhibits the tumorigenesis and metastasis of breast cancer via downregulating CIZ1 expression associated with TGF-β1 signaling [J]. Life Sci, 2020, 248: 117454.
Hong Y N, Fan D D. Ginsenoside Rk₁ induces cell cycle arrest and apoptosis in MDA-MB-231 triple negative breast cancer cells [J]. Toxicology, 2019, 418: 22-31.
Xia J X, Ma S J, Zhu X, et al. Versatile ginsenoside Rg₃ liposomes inhibit tumor metastasis by capturing circulating tumor cells and destroying metastatic niches [J]. Sci Adv, 2022, 8(6): eabj1262.
Chu Y, Zhang W T, Kanimozhi G, et al. Ginsenoside Rg₁ induces apoptotic cell death in triple-negative breast cancer cell lines and prevents carcinogen-induced breast tumorigenesis in sprague dawley rats [J]. Evid Based Complement Alternat Med, 2020, 2020: 8886955.
马文静. 马钱子碱对裸鼠乳腺癌骨转移的实验研究[D]. 合肥: 安徽医科大学, 2009.
Kunihiro A G, Brickey J A, Frye J B, et al. Curcumin Inhibition of TGFβ signaling in bone metastatic breast cancer cells and the possible role of oxidative metabolites [J]. J Nutr Biochem, 2022, 99: 108842.
Kunihiro A G, Brickey J A, Frye J B, et al. Curcumin, but not curcumin-glucuronide, inhibits Smad signaling in TGFβ-dependent bone metastatic breast cancer cells and is enriched in bone compared to other tissues [J]. J Nutr Biochem, 2019, 63: 150-156.
Abdellatef A A, Fathy M, Mohammed A E I, et al. Inhibition of cell-intrinsic NF-κB activity and metastatic abilities of breast cancer by Aloe-emodin and emodic-acid isolated from Asphodelus microcarpus [J]. J Nat Med, 2021, 75(4): 840-853.
Wang Y J, Zhong Z Y, Ma M, et al. The role played by ailanthone in inhibiting bone metastasis of breast cancer by regulating tumor-bone microenvironment through the RANKL-dependent pathway [J]. Front Pharmacol, 2023, 13: 1081978.
高洁琼, 王俊涛, 王祥麒. 乳腺癌骨转移的中医药治疗研究进展[J]. 中医药通报, 2016, 15(1): 69-71.
叶林霜, 鲁婷, 张美玲, 等. 基于网络药理学和分子对接探讨左归丸“异病同治”阿尔茨海默病和骨质疏松的作用机制[J]. 药物评价研究, 2025, 34(12): 3613-3626.
赵旭, 周才杰, 陈龙娇. 左归丸对乳腺癌骨转移“标本同治”的潜在机制研究[J]. 中医药通报, 2025, 24(7): 35-43.
顾金光, 董永丽, 李辰华, 等. 左归丸经ERK/ETS1/ PPARγ信号通路促进MC3T3-E1细胞增殖与成骨分化[J]. 中国骨质疏松杂志, 2025, 31(8): 1142-1151.
付剑江, 梅殷珑, 麻俊超, 等. 左归丸通过调控p38 MAPK/ERK信号通路抑制乳腺癌诱导的破骨细胞活化及机制[J]. 中国实验方剂学杂志, 2025, 31(1): 1-9.
曹玉琪, 徐亚南, 孙佳归, 等. 炮附子在经方汤剂中的应用规律探析[J]. 辽宁中医药大学学报, 2025, 27(1): 102-107.
刘琦, 程旭锋, 张新峰, 等. 附子白术汤通过调节OPG/RANKL保护乳腺癌骨转移裸鼠骨损伤的研究[J]. 中国实验方剂学杂志, 2013, 19(15): 206-210.
程旭锋, 张新峰, 刘琦, 等. 附子-白术药对对乳腺癌骨转移裸鼠TGF-β/Smads/Gli2/PTHrP信号通路的影响[J]. 中国实验方剂学杂志, 2017, 23(24): 128-132.
龙鑫, 张智敏. 白术附子汤加味治疗乳腺癌骨转移的临床疗效评价[J]. 内蒙古中医药, 2017, 36(8): 42-43.
汪俊杰, 郑英杰, 陈蓓. 阳和汤在骨关节疾病的应用[J]. 光明中医, 2025, 40(2): 386-389.
田清予, 罗宗键. 阳和汤治疗膝骨关节炎的作用机制研究进展[J]. 当代医药论丛, 2025, 23(14): 15-17.
田莎, 王云丹, 黄立中, 等. 阳和汤对裸鼠移植性乳腺癌骨转移模型作用机制的探讨[J]. 湖南中医药大学学报, 2012, 32(7): 27-30.
冯磊, 毛丹, 陈州华, 等. 基于RANK/RANKL/OPG系统探讨阳和汤对阳虚证乳腺癌骨转移裸鼠模型的影响[J]. 北京中医药, 2017, 36(1): 27-32.
冯磊, 李玲, 李阳, 等. 阳和汤联合唑来膦酸治疗阳虚寒凝型乳腺癌骨转移30例[J]. 湖南中医杂志, 2022, 38(10): 12-16.
向晓东, 林玲, 刘菊. 补肾活血汤及加减方治疗骨质疏松症研究进展[J]. 中国社区医师, 2023, 39(26): 8-10.
胡玉蝶. 补肾活血汤通过下调BSP、Src、PTHrP、NFATc1表达减少破骨细胞生成治疗乳腺癌骨转移[D]. 长沙: 湖南中医药大学, 2023.
孟树. 补肾活血汤对裸鼠乳腺癌骨转移模型及OPG/ RANK/RANKL系统影响的研究[D]. 长沙: 湖南中医药大学, 2019.
Huang Q L, Ning H J, Wang J, et al. Wenshen Zhuanggu Formula inhibits tumor-exosomes induced bone pre-metastasis niche formation in primary breast cancer mice [J]. Chin Med, 2025, 20(1): 88.
Chen W L, Li J J, Sun Z P, et al. Comparative pharmacokinetics of six coumarins in normal and breast cancer bone-metastatic mice after oral administration of Wenshen Zhuanggu Formula [J]. J Ethnopharmacol, 2018, 224: 36-44.
李琼, 刘胜, 杨顺芳. 补骨脂与蛇床子抑制乳腺癌骨转移的体内实验[J]. 上海中医药大学学报, 2010, 24(1): 53-58.
陈智佳. 中医治疗对乳腺癌骨转移疗效的网状Meta分析[D]. 南昌: 江西中医药大学, 2024.
张鑫, 刘民, 黄艺珊, 等. 中药及其方剂药动学的发展历程和展望[J]. 中草药, 2025, 56(15): 5605-5615.
Hu Q R, Hong H, Zhang Z H, et al. Methods on improvements of the poor oral bioavailability of ginsenosides: Pre-processing, structural modification, drug combination, and micro- or nano- delivery system [J]. J Ginseng Res, 2023, 47(6): 694-705.
阮慧妮, 丁文雅, 杨旭, 等. 中药皂苷类成分纳米制剂的研究进展[J]. 中国医院药学杂志, 2025, 45(7): 827-833.
马洁, 卢倩, 田锁燕, 等. 中药药代动力学的异质性研究进展[J]. 时珍国医国药, 2025, 36(4): 722-727.
顾杰, 汪祺, 赵宇新, 等. 基于中药监管科学的中药制剂质量标准研究策略与方法[J]. 中国药学杂志, 2025, 60(2): 121-129.
房立源. 独活寄生汤加减治疗绝经后Luminal型乳腺癌骨转移(肝肾阴虚型)的临床研究[D]. 济南: 山东中医药大学, 2022.
Li F F, Shi Y Y, Ma M, et al. Xianling Lianxia Formula improves the efficacy of trastuzumab by enhancing NK cell-mediated ADCC in HER2-positive BC [J]. J Pharm Anal, 2024, 14(10): 100977.
吴沁航, 朱丽文, 李铭轩, 等. 中药抗三阴性乳腺癌及其分子作用机制研究进展[J]. 南京中医药大学学报, 2021, 37(4): 602-608.
Guo Q J, Lin J Y, Liu R, et al. Review on the applications and molecular mechanisms of Xihuang Pill in tumor treatment [J]. Evid Based Complement Alternat Med, 2015, 2015: 854307.
杨争, 陈雪珍, 胡金辉. 中药联合唑来磷酸治疗乳腺癌骨转移疗效Meta分析[J]. 中医药临床杂志, 2020, 32(12): 2270-2276.
刘军, 梁惠. 填精益髓止痛方联合中药热奄包治疗乳腺癌骨转移疼痛的临床观察[J]. 中医药导报, 2020, 26(16): 115-118.

2026年第57卷第4期

PDF下载

引用本文

BibTeX

文章信息

doi: 10.7501/j.issn.0253-2670.2026.04.025

接收时间：2025-09-05
首发时间：2026-09-09

补充材料

相关文章

文章信息

作者

出版历史

收稿日期：2025-09-05

基金

作者信息

参考文献

分享链接

https://castjournals.cast.org.cn/joweb/zcy/CN/10.7501/j.issn.0253-2670.2026.04.025

分享至

全文二维码

扫描看全文

引用本文

BibTeX

本文的引用情况

2种不同金属材料的力学参数

科 Family	属数 Number of genus	种数 Number of species	占总种数比例 Percentage of total species (%)	属 Genus	种数 Number of species	占总种数比例 Percentage of total species (%)
鹅膏菌科Amanitaceae	2	11	5.26	鹅膏菌属 Amanita	10	4.78
小菇科 Mycenaceae	2	12	5.74	丝盖伞属 Inocybe	5	2.39
多孔菌科 Polyporaceae	8	14	6.70	蜡蘑属 Laccaria	5	2.39
红菇科 Russulaceae	3	23	11.00	小皮伞属 Marasmius	6	2.87
				小菇属 Mycena	11	5.26
				光柄菇属 Pluteus	5	2.39
				红菇属 Russula	17	8.13
				栓菌属 Trametes	5	2.39

关闭全屏

BibTeX
EndNote
RefWorks
TxT